LSTA Lisata Therapeutics, Inc.
Distress ·
Kuva Labs could not raise the money to complete its $4.00 tender offer for Lisata. Lisata then cut about 72% of its staff, and on Sept 17 it bought Marea with a $225 million private placement that heavily dilutes existing holders.
Lisata and Kuva Labs signed an amendment and waiver on May 3, 2026 that moves the tender offer start from April 13, 2026 to May 29, 2026. Kuva will pay up to $1.1 million of Lisata's expenses until the offer starts, and the offer is $5.00 in cash plus a $1.00 contingent value right.
Lisata and Kuva Labs agreed on April 2, 2026 to move the tender offer start from April 3 to April 13, 2026, or a later agreed date. The offer pays $5.00 in cash plus a $1.00 contingent right, and Lisata's 10-K says its $16.0 million in cash does not cover twelve months of spending.
| Line | FY2025 | FY2024 |
|---|---|---|
| Net income (loss) | -$16.6 million | -$20.0 million |
| Cash from operations | -$15.9 million | -$19.4 million |
| Cash and equivalents | $16.0 million | $16.2 million |
Our latest story on this, dated Aug 3, 2026: "Lisata cuts 72% of staff after failed Kuva buyout, then merges with Marea". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 3, 2026: "Lisata cuts 72% of staff after failed Kuva buyout, then merges with Marea". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 3, 2026: "Lisata cuts 72% of staff after failed Kuva buyout, then merges with Marea". The story links the filing or release it is based on. Read the story.
Lisata Therapeutics, Inc. trades under the ticker LSTA on NASDAQ.
Lisata Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:8NE; LSE:0HS8.
The SEC Central Index Key (CIK) for Lisata Therapeutics, Inc. is 320017. Its filings are on SEC EDGAR.
9,010,937 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Lisata Therapeutics, Inc. under United States.
Our directory classifies Lisata Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Lisata Therapeutics, Inc. is US1280583022.
aibio.space lists Lisata Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Lisata Therapeutics, Inc. reported a net loss of $16.6 million for the fiscal year ended Dec 31, 2025, and used $15.9 million of cash in operations, per its annual report to the SEC.
$10.4 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Lisata Therapeutics, dated Aug 3, 2026: "Lisata cuts 72% of staff after failed Kuva buyout, then merges with Marea". Kuva Labs could not raise the money to complete its $4.00 tender offer for Lisata. Lisata then cut about 72% of its staff, and on Sept 17 it bought Marea with a $225 million private placement that heavily dilutes existing holders. Source.
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02,8.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,8.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio